Emerald-3, Successor-2 and Optimum-02 studies secure late-breaker spots.
ApexOnco Front Page
Recent articles
The company drops the anti-CD19 x 4-1BB project englumafusp alfa.
A $3.15bn deal follows a December 2024 option agreement.
The groups spend big on Terns and Arcellx.
Rinzimetostat efficacy wanes further as the company moves into phase 3.
J&J’s Tecvayli/Darzalex nod was the second under a new priority voucher scheme.
The group wants to improve on its own Welireg in a new phase 3 trial.
Replimune gets a second chance, while Sarclisa could go subcutaneous.
